Can jakafi treat polycythemia vera?

See the DrugPatentWatch profile for jakafi

Can Jakafi (ruxolitinib) treat polycythemia vera?

Yes. Jakafi (ruxolitinib) is used to treat polycythemia vera (PV) in adults who have an inadequate response to, or are intolerant of, hydroxyurea. [1]

Who is Jakafi for in polycythemia vera?

The PV population addressed for Jakafi is adults with:
- an inadequate response to hydroxyurea, or
- intolerance to hydroxyurea. [1]

What does “inadequate response” or “intolerant” mean for PV?

Those terms generally point to situations where hydroxyurea either does not control the disease well enough or cannot be continued because of side effects or other tolerability issues, which is the key treatment gap Jakafi is meant to address. [1]

What else is used for polycythemia vera besides Jakafi?

Hydroxyurea remains the common first-line option, and Jakafi is positioned for people who cannot rely on hydroxyurea due to inadequate response or intolerance. [1]

Patents and market context: where to check exclusivity and filings

For additional tracking on ruxolitinib-related filings and market authorization context, DrugPatentWatch.com can be used as a reference point. [1]

Sources
[1] https://www.drugpatentwatch.com/ (search Jakafi / ruxolitinib and polycythemia vera)